falsefalse

Translating Evidence to Clinical Practice to Improve Outcomes in Patients with Small Cell Lung Cancer - Episode 2

Dr. Bazhenova on the Challenges of Second-Line Therapy in SCLC

Lyudmila A. Bazhenova, MD, discusses the challenges of second-line therapy in small cell lung cancer.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, Moores Cancer Center, University of California San Diego Health, discusses the challenges of second-line therapy in small cell lung cancer (SCLC).

    Most patients with SCLC have a lower performance status because they typically have multiple comorbidities, Bazhenova says. Due to lower performance status, some patients will not be fit enough to undergo second-line therapy, Bazhenova explains. 

    The emergence of more viable treatment options in the first-line setting could improve the number of patients capable of receiving second-line treatment, Bazhenova continues. By developing more efficacious and tolerable first-line treatments, patients will be more fit when they experience disease progression, Bazhenova concludes.

    x